International Minerals & Chemical subsidiary Mallinckrodt acquires minority equity position in Seattle-based monoclonal antibody research firm NeoRx. Mallinckrodt will recieve "certain exclusive technology, product development and marketing rights in the field of radioisotopic imaging agents utilizing monoclonal antibodies," a March 18 release notes. Under the agreement, Mallinckrodt will get access to diagnostic products stemming from NeoRx research in the monoclonal antibody area.
You may also be interested in...
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.
A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert Bourla.